首页> 美国卫生研究院文献>Molecular Brain >Restoring synaptic plasticity and memory in mouse models of Alzheimer’s disease by PKR inhibition
【2h】

Restoring synaptic plasticity and memory in mouse models of Alzheimer’s disease by PKR inhibition

机译:通过PKR抑制恢复阿尔茨海默氏病小鼠模型的突触可塑性和记忆

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with deficits in cognition and synaptic plasticity. While accumulation of amyloid β (Aβ) and hyper-phosphorylation of tau are parts of the etiology, AD can be caused by a large number of different genetic mutations and other unknown factors. Considering such a heterogeneous nature of AD, it would be desirable to develop treatment strategies that can improve memory irrespective of the individual causes. Reducing the phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) was shown to enhance long-term memory and synaptic plasticity in naïve mice. Moreover, hyper-phosphorylation of eIF2α is observed in the brains of postmortem AD patients. Therefore, regulating eIF2α phosphorylation can be a plausible candidate for restoring memory in AD by targeting memory-enhancing mechanism. In this study, we examined whether PKR inhibition can rescue synaptic and learning deficits in two different AD mouse models; 5XFAD transgenic and Aβ1–42-injected mice. We found that the acute treatment of PKR inhibitor (PKRi) can restore the deficits in long-term memory and long-term potentiation (LTP) in both mouse models without affecting the Aβ load in the hippocampus. Our results prove the principle that targeting memory enhancing mechanisms can be a valid candidate for developing AD treatment.Electronic supplementary materialThe online version of this article (10.1186/s13041-017-0338-3) contains supplementary material, which is available to authorized users.
机译:阿尔茨海默氏病(AD)是一种神经退行性疾病,与认知能力和突触可塑性缺乏有关。虽然淀粉样蛋白β(Aβ)的积累和tau的过度磷酸化是病因的一部分,但AD可能是由大量不同的基因突变和其他未知因素引起的。考虑到AD的这种异质性,期望开发出可以改善记忆的治疗策略,而不论个体原因如何。减少真核翻译起始因子2α(eIF2α)的磷酸化可增强幼稚小鼠的长期记忆和突触可塑性。此外,在死后AD患者的脑中观察到eIF2α的过度磷酸化。因此,通过靶向记忆增强机制,调节eIF2α磷酸化可能是恢复AD记忆的合理选择。在这项研究中,我们检查了PKR抑制是否可以挽救两种不同AD小鼠模型中的突触和学习缺陷。 5XFAD转基因和Aβ1-42注射小鼠。我们发现,急性治疗PKR抑制剂(PKRi)可以在两种小鼠模型中恢复长期记忆和长期增强(LTP)的缺陷,而不会影响海马中的Aβ负荷。我们的结果证明了靶向记忆增强机制可以成为开发AD治疗的有效候选者的原则。电子补充材料本文的在线版本(10.1186 / s13041-017-0338-3)包含补充材料,可供授权用户使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号